165 related articles for article (PubMed ID: 38477582)
1. Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein.
Ketcham JM; Harwood SJ; Aranda R; Aloiau AN; Bobek BM; Briere DM; Burns AC; Caddell Haatveit K; Calinisan A; Clarine J; Elliott A; Engstrom LD; Gunn RJ; Ivetac A; Jones B; Kuehler J; Lawson JD; Nguyen N; Parker C; Pearson KE; Rahbaek L; Saechao B; Wang X; Waters A; Waters L; Watkins AH; Olson P; Smith CR; Christensen JG; Marx MA
J Med Chem; 2024 Mar; 67(6):4936-4949. PubMed ID: 38477582
[TBL] [Abstract][Full Text] [Related]
2. Docking studies on isoform-specific inhibition of phosphoinositide-3-kinases.
Sabbah DA; Vennerstrom JL; Zhong H
J Chem Inf Model; 2010 Oct; 50(10):1887-98. PubMed ID: 20866085
[TBL] [Abstract][Full Text] [Related]
3. Comparative molecular dynamics analyses on PIK3CA hotspot mutations with PI3Kα specific inhibitors and ATP.
Menteş M; Karakuzulu BB; Uçar GB; Yandım C
Comput Biol Chem; 2022 Aug; 99():107726. PubMed ID: 35842959
[TBL] [Abstract][Full Text] [Related]
4. Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα.
Hanan EJ; Braun MG; Heald RA; MacLeod C; Chan C; Clausen S; Edgar KA; Eigenbrot C; Elliott R; Endres N; Friedman LS; Gogol E; Gu XH; Thibodeau RH; Jackson PS; Kiefer JR; Knight JD; Nannini M; Narukulla R; Pace A; Pang J; Purkey HE; Salphati L; Sampath D; Schmidt S; Sideris S; Song K; Sujatha-Bhaskar S; Ultsch M; Wallweber H; Xin J; Yeap S; Young A; Zhong Y; Staben ST
J Med Chem; 2022 Dec; 65(24):16589-16621. PubMed ID: 36455032
[TBL] [Abstract][Full Text] [Related]
5. DW09849, a selective phosphatidylinositol 3-kinase (PI3K) inhibitor, prevents PI3K signaling and preferentially inhibits proliferation of cells containing the oncogenic mutation p110α (H1047R).
Liu JL; Gao GR; Zhang X; Cao SF; Guo CL; Wang X; Tong LJ; Ding J; Duan WH; Meng LH
J Pharmacol Exp Ther; 2014 Mar; 348(3):432-41. PubMed ID: 24361696
[TBL] [Abstract][Full Text] [Related]
6. Combining properties of different classes of PI3Kα inhibitors to understand the molecular features that confer selectivity.
Gong GQ; Kendall JD; Dickson JMJ; Rewcastle GW; Buchanan CM; Denny WA; Shepherd PR; Flanagan JU
Biochem J; 2017 Jun; 474(13):2261-2276. PubMed ID: 28526744
[TBL] [Abstract][Full Text] [Related]
7. Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia.
Varkaris A; Pazolli E; Gunaydin H; Wang Q; Pierce L; Boezio AA; Bulku A; DiPietro L; Fridrich C; Frost A; Giordanetto F; Hamilton EP; Harris K; Holliday M; Hunter TL; Iskandar A; Ji Y; Larivée A; LaRochelle JR; Lescarbeau A; Llambi F; Lormil B; Mader MM; Mar BG; Martin I; McLean TH; Michelsen K; Pechersky Y; Puente-Poushnejad E; Raynor K; Rogala D; Samadani R; Schram AM; Shortsleeves K; Swaminathan S; Tajmir S; Tan G; Tang Y; Valverde R; Wehrenberg B; Wilbur J; Williams BR; Zeng H; Zhang H; Walters WP; Wolf BB; Shaw DE; Bergstrom DA; Watters J; Fraser JS; Fortin PD; Kipp DR
Cancer Discov; 2024 Feb; 14(2):240-257. PubMed ID: 37916956
[TBL] [Abstract][Full Text] [Related]
8. In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA.
Kong D; Yamori T; Yamazaki K; Dan S
Invest New Drugs; 2014 Dec; 32(6):1134-43. PubMed ID: 25152245
[TBL] [Abstract][Full Text] [Related]
9. Cryo-EM structures reveal two allosteric inhibition modes of PI3Kα
Huang X; Wang K; Han J; Chen X; Wang Z; Wu T; Yu B; Zhao F; Wang X; Li H; Xie Z; Zhu X; Zhong W; Ren X
Structure; 2024 Mar; ():. PubMed ID: 38582077
[TBL] [Abstract][Full Text] [Related]
10. Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016-2020).
Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
Expert Opin Ther Pat; 2021 Oct; 31(10):877-892. PubMed ID: 33970742
[No Abstract] [Full Text] [Related]
11. Synthesis, biological evaluation and structure-activity relationship of a novel class of PI3Kα H1047R mutant inhibitors.
Zhang N; Yu Z; Yang X; Zhou Y; Wang J; Zhang SL; Wang MW; He Y
Eur J Med Chem; 2018 Oct; 158():707-719. PubMed ID: 30245395
[TBL] [Abstract][Full Text] [Related]
12. N-Phenyl-4-hydroxy-2-quinolone-3-carboxamides as selective inhibitors of mutant H1047R phosphoinositide-3-kinase (PI3Kα).
Sabbah DA; Simms NA; Wang W; Dong Y; Ezell EL; Brattain MG; Vennerstrom JL; Zhong HA
Bioorg Med Chem; 2012 Dec; 20(24):7175-83. PubMed ID: 23121722
[TBL] [Abstract][Full Text] [Related]
13. Cryo-EM structures of cancer-specific helical and kinase domain mutations of PI3Kα.
Liu X; Zhou Q; Hart JR; Xu Y; Yang S; Yang D; Vogt PK; Wang MW
Proc Natl Acad Sci U S A; 2022 Nov; 119(46):e2215621119. PubMed ID: 36343266
[TBL] [Abstract][Full Text] [Related]
14. Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations.
Varkaris A; Fece de la Cruz F; Martin EE; Norden BL; Chevalier N; Kehlmann AM; Leshchiner I; Barnes H; Ehnstrom S; Stavridi AM; Yuan X; Kim JS; Ellis H; Papatheodoridi A; Gunaydin H; Danysh BP; Parida L; Sanidas I; Ji Y; Lau K; Wulf GM; Bardia A; Spring LM; Isakoff SJ; Lennerz JK; Del Vecchio K; Pierce L; Pazolli E; Getz G; Corcoran RB; Juric D
Cancer Discov; 2024 Feb; 14(2):227-239. PubMed ID: 37916958
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4-triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): A potent and selective inhibitor of PI3Kα and PI3Kδ for the treatment of cancers.
Barlaam B; Cosulich S; Delouvrié B; Ellston R; Fitzek M; Germain H; Green S; Hancox U; Harris CS; Hudson K; Lambert-van der Brempt C; Lebraud H; Magnien F; Lamorlette M; Le Griffon A; Morgentin R; Ouvry G; Page K; Pasquet G; Polanska U; Ruston L; Saleh T; Vautier M; Ward L
Bioorg Med Chem Lett; 2015 Nov; 25(22):5155-62. PubMed ID: 26475521
[TBL] [Abstract][Full Text] [Related]
16. Exploring a non-ATP pocket for potential allosteric modulation of PI3Kα.
Gkeka P; Papafotika A; Christoforidis S; Cournia Z
J Phys Chem B; 2015 Jan; 119(3):1002-16. PubMed ID: 25299356
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.
Fritsch C; Huang A; Chatenay-Rivauday C; Schnell C; Reddy A; Liu M; Kauffmann A; Guthy D; Erdmann D; De Pover A; Furet P; Gao H; Ferretti S; Wang Y; Trappe J; Brachmann SM; Maira SM; Wilson C; Boehm M; Garcia-Echeverria C; Chene P; Wiesmann M; Cozens R; Lehar J; Schlegel R; Caravatti G; Hofmann F; Sellers WR
Mol Cancer Ther; 2014 May; 13(5):1117-29. PubMed ID: 24608574
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.
Merino VF; Cho S; Liang X; Park S; Jin K; Chen Q; Pan D; Zahnow CA; Rein AR; Sukumar S
Mol Oncol; 2017 May; 11(5):552-566. PubMed ID: 28296140
[TBL] [Abstract][Full Text] [Related]
19. Double
Vasan N; Razavi P; Johnson JL; Shao H; Shah H; Antoine A; Ladewig E; Gorelick A; Lin TY; Toska E; Xu G; Kazmi A; Chang MT; Taylor BS; Dickler MN; Jhaveri K; Chandarlapaty S; Rabadan R; Reznik E; Smith ML; Sebra R; Schimmoller F; Wilson TR; Friedman LS; Cantley LC; Scaltriti M; Baselga J
Science; 2019 Nov; 366(6466):714-723. PubMed ID: 31699932
[TBL] [Abstract][Full Text] [Related]
20. Investigating the structure and dynamics of the PIK3CA wild-type and H1047R oncogenic mutant.
Gkeka P; Evangelidis T; Pavlaki M; Lazani V; Christoforidis S; Agianian B; Cournia Z
PLoS Comput Biol; 2014 Oct; 10(10):e1003895. PubMed ID: 25340423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
